Replimune surges after FDA panel votes in favor of skin cancer drug
31/07/2026 11:37
BUZZ-Replimune surges after FDA panel votes in favor of skin cancer drug ** Shares of drug developer Replimune REPL.O more than double to $12.41 premarket
** US FDA's panel of outside advisers on Thursday voted to back results from a trial studying the company's drug for a type of skin cancer
** REPL seeks accelerated approval for RP1 in combination with Bristol Myers Squibb's BMY.N Opdivo in advanced melanoma in patients whose tumors grew despite prior treatment, with a decision expected by August 2
** "Given the media attention surrounding this decision, we think it's a near certainty that the FDA follows the panel's advice" - Cantor Fitzgerald
** Brokerage assumes unadjusted peak U.S. sales of $708 million by 2040 for RP1
** Up to last close, stock down 44.3% YTD
(Reporting by Sneha S K)
Recent news on Replimune
See all newsTrump picks White House adviser Heidi Overton to run FDA, source says (updated)
Brief: Replimune Group, Inc. Files For Mixed Shelf Size Not Disclosed
Brief: Replimune Reports Fiscal First Quarter 2027 Financial Results And Provides Corporate Update
Replimune Q1 net loss narrows as expenses decline
U.S. STOCKS ON THE MOVE-Microsoft, Coastal Financial, Eli Lilly